MacroGenics (NASDAQ:MGNX) VP Jeffrey Stuart Peters Sells 31,105 Shares

MacroGenics, Inc. (NASDAQ:MGNX) VP Jeffrey Stuart Peters sold 31,105 shares of MacroGenics stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $4.15, for a total value of $129,085.75. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

MacroGenics Trading Down 2.4%

Shares of NASDAQ MGNX opened at $4.07 on Friday. The company has a market capitalization of $259.26 million, a price-to-earnings ratio of -18.50 and a beta of 1.20. MacroGenics, Inc. has a twelve month low of $1.29 and a twelve month high of $5.08. The business has a 50 day simple moving average of $4.24 and a 200-day simple moving average of $3.46.

MacroGenics (NASDAQ:MGNX) last announced its quarterly earnings data on Thursday, August 13th. The biopharmaceutical company reported $0.31 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.08) by $0.39. MacroGenics had a negative return on equity of 109.26% and a negative net margin of 8.70%.The firm had revenue of $32.83 million for the quarter, compared to analysts’ expectations of $59.14 million. As a group, equities analysts predict that MacroGenics, Inc. will post -1.48 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of MacroGenics in a research report on Wednesday, August 5th. B. Riley Financial lifted their target price on MacroGenics from $9.00 to $11.00 and gave the company a “buy” rating in a research note on Monday. Two analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, MacroGenics has an average rating of “Hold” and an average price target of $6.33.

Institutional Investors Weigh In On MacroGenics

Hedge funds have recently added to or reduced their stakes in the stock. Invesco Ltd. lifted its stake in shares of MacroGenics by 90.0% in the 1st quarter. Invesco Ltd. now owns 68,377 shares of the biopharmaceutical company’s stock worth $87,000 after acquiring an additional 32,398 shares during the period. Amundi acquired a new position in shares of MacroGenics in the 1st quarter worth $272,000. Jones Financial Companies Lllp boosted its position in shares of MacroGenics by 456,243.3% in the 1st quarter. Jones Financial Companies Lllp now owns 136,903 shares of the biopharmaceutical company’s stock valued at $174,000 after purchasing an additional 136,873 shares during the period. Russell Investments Group Ltd. boosted its position in shares of MacroGenics by 2,970.9% in the 2nd quarter. Russell Investments Group Ltd. now owns 49,564 shares of the biopharmaceutical company’s stock valued at $59,000 after purchasing an additional 47,950 shares during the period. Finally, Walleye Capital LLC purchased a new position in MacroGenics in the 2nd quarter worth about $30,000. 96.89% of the stock is currently owned by institutional investors.

MacroGenics Company Profile

MacroGenics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of monoclonal antibody–based therapeutics for the treatment of cancer and autoimmune diseases. The company leverages proprietary Fc engineering technologies to enhance immune engagement and extend the activity of its antibodies. Since its founding in 2000, MacroGenics has advanced several product candidates through clinical trials, most notably margetuximab, a HER2-targeted antibody designed to improve outcomes in patients with HER2-positive breast cancer.

Central to MacroGenics’ research platform are its ADAPTIR and Trident bispecific antibody technologies.